miR-1248 enhances bortezomib-induced autophagy by targeting MEF2C/p38-MAPK signaling in multiple myeloma - Takeaways - MDSpire

miR-1248 enhances bortezomib-induced autophagy by targeting MEF2C/p38-MAPK signaling in multiple myeloma

  • By

  • Wei Wang

  • Rong-juan Zhang

  • Ming-shuai Ma

  • Xiao-min Shi

  • Qing Zhang

  • Chong Li

  • Zhi-hua Zhang

  • Chang-lai Hao

  • June 26, 2026

  • 0 min

Share

  • 1

    miR-1248 is significantly upregulated in multiple myeloma cells after bortezomib treatment, indicating its potential role in drug response.

  • 2

    Bortezomib treatment reduces MEF2C mRNA and protein levels, suggesting a regulatory relationship between miR-1248 and MEF2C.

  • 3

    Inhibiting miR-1248 decreases autophagy markers and partially restores MEF2C and p38 expression in bortezomib-treated cells.

  • 4

    Overexpression of MEF2C enhances cell viability and reduces bortezomib-induced apoptosis, indicating its role in drug resistance.

  • 5

    In vivo studies show that miR-1248 knockdown significantly reduces tumor inhibition in response to bortezomib, highlighting its therapeutic potential.

Original Source(s)

miR-1248 enhances bortezomib-induced autophagy by targeting MEF2C/p38-MAPK signaling in multiple myeloma

  • by Wei Wang, Rong-juan Zhang, Ming-shuai Ma, Xiao-min Shi, Qing Zhang, Chong Li, Zhi-hua Zhang, Chang-lai Hao

  • June 26, 2026

Related Content

Solution for the hot spots in adaptive radiotherapy planning for cervical cancer: a case report and review of literature

Correction: Follicular dendritic cell sarcoma associated with IgG4-related disease: a case report and literature review

Algebraic evaluation of optimization in tumors classification with numerical assessments via a flask–react web interface